Liquidia Corporation Common Stock vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Liquidia Corporation Common Stock trades at $33.69 (market cap $2.40B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.84 (market cap $1.46B). The key difference: Liquidia Corporation Common Stock is the larger of the two by market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 50 Days on average.
| LQDA | QQQE | |
|---|---|---|
Market Cap | $2.40B | $1.46B |
Volume | 2,857,547 | 175,669 |
Sector | Health | Broad Market / Factor |
52-Week High | $91.03 | $124.69 |
52-Week Low | $22.02 | $96.06 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $120.45, down 0.4% on the day with a bearish technical signal from moving averages. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning over the next twelve months.
The equal-weight approach provides diversification benefits amid tech sector volatility, though the bearish technical trend and neutral oscillators suggest near-term consolidation. Key risks include NASDAQ concentration and market volatility, while the strategy appeals to investors seeking reduced tech exposure within large-cap growth stocks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →